)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sanofi India
Sanofi India (500674) investor relations material
Sanofi India Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
Q3 2026 net sales grew 4% YoY, with domestic sales up 2%; profit before tax (PBT) before exceptional items rose 22% to ₹1,577mn.
Q3 PAT increased 54% YoY to ₹1,167mn, supported by diabetes growth, favorable product mix and lower operating expenses.
Financial highlights
Revenue from operations was ₹4,917mn in Q3 2026 vs ₹4,754mn in Q3 2025; 9M revenue was ₹14,017mn vs ₹14,176mn.
9M PAT rose to ₹3,028mn from ₹2,650mn; 9M EPS was ₹131.48 vs ₹115.06.
Q3 total comprehensive income was ₹1,167mn vs ₹760mn YoY; 9M total comprehensive income was ₹3,028mn vs ₹2,650mn.
Outlook and guidance
Diabetes injectables, a modernized go-to-market model and widening public-sector access were described as foundations for sustainable long-term value creation.
Strategic partnerships continue to expand commercial reach; performance strengthening remains a focus.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sanofi India
- Q2 2026 profit before tax rose 19% on double-digit diabetes growth and margin expansion.500674
Q2 2026 - Insulin portfolio achieved 14% sequential and 19% year-over-year growth amid leadership changes.500674Q1 2026
- Net profit rose to ₹3,267m; diabetes led growth; total dividend proposed at ₹123/share.500674Q4 2025
- Margin and profit growth driven by diabetes focus, digital tools, and operational efficiency.500674Q3 2025
- Sequential revenue and profit declined, with leadership changes and a new OAD distribution deal.500674Q2 2025
- Q3 2024 saw 8% sales growth and a successful demerger, with strong diabetes portfolio gains.500674Q3 2024
- Demerger, supply issues, and restructuring shaped Q2, but diabetes brands led market growth.500674Q2 2024
- Q1-2025 saw 4% sales growth and 27% higher operating profit, with continued focus on innovation.500674Q1 2025
- Q4-2024 net sales rose 8% and a ₹117/share dividend was recommended for FY2024.500674Q4 2024
Next Sanofi India earnings date
Q4 202625 Feb, 2027
Sanofi India
Next Sanofi India earnings date
Q4 202625 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sanofi India Limited is an Indian pharmaceutical company engaged in the manufacturing and marketing of prescription medicines and consumer healthcare products. It offers treatments in therapeutic areas such as diabetes, cardiovascular diseases, central nervous system disorders, and dermatology. The company is a subsidiary of global healthcare company Sanofi. It is headquartered in Mumbai, India, and its shares are listed on the BSE.